Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by stimulating the mother’s immune system to produce defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence indicating that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent coverage when vaccinated 4 weeks before birth
• Maternal antibodies transferred through the placenta protect newborns from birth
• Coverage possible with two-week gap before early delivery
• Vaccination in third trimester still offers significant infant protection

Persuasive evidence from current research

The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study conducted across England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s actual performance. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation provides healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across varied populations and settings.

The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s critical role in protecting against serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Study design and parameters

The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology captured practical outcomes rather than experimental conditions, providing tangible evidence of how the vaccine performs when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Learning about RSV and the threats

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection triggers deep inflammation in the lungs and airways, making it perilously hard for affected infants to breathe and feed effectively. Parents frequently observe their babies struggling visibly, their chests heaving as they attempt to draw sufficient oxygen into their compromised lungs. Whilst the majority of babies recover with palliative treatment, a modest yet notable number die from RSV-related complications annually, making prevention through vaccination a critical public health priority for protecting the most vulnerable and youngest people in our communities.

• RSV causes inflammation in lungs, causing serious respiratory problems in infants
• Approximately half of infants catch the infection during their first few months alive
• Symptoms range from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK babies require serious hospital care for RSV each year
• Few infants die from RSV related complications annually in the UK

Take-up rates and professional guidance

Since the RSV vaccine programme began in 2024, health officials have emphasised the value of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides nearly 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies through the placenta.

The messaging from public health bodies stays clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.

Regional differences in vaccine uptake

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.

• NHS trusts deploying varied communication campaigns to connect with expectant mothers
• Inconsistencies across regions in immunisation take-up across England necessitate strategic intervention
• Local healthcare systems adapting programmes to suit local requirements and situations

Practical implications and parental perspectives

The vaccine’s impressive effectiveness delivers tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the launch of this protective measure, the 80% drop in admissions means thousands of infants shielded from serious illness. Parents no longer face the distressing scenario of seeing their babies struggle for breath or difficulty feeding, symptoms that define critical RSV illness. The vaccine has substantially transformed the landscape of neonatal breathing health, providing expectant mothers a active means to safeguard their most vulnerable children during those crucial first weeks.

For families like that of Malachi, whose severe RSV infection led to severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s support of the jab highlights the profound consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers during their late pregnancy, converting what was once an predictable seasonal threat into a manageable health risk.